[메가경제=양대선 기자] Biobytes has announced its full-scale entry into the global market following the signing of a Strategic Memorandum of Understanding (MOU) and a Non-Disclosure Agreement (NDA) with Canadian sarcopenia molecular diagnostics firm, Myomar Molecular Inc (hereinafter Myomar).
Specialized in drug biomarker discovery based on sarcopenia biobank cohort data, Biobytes previously collaborated with Hyundai Engineering and Construction via the Seoul Startup Hub Gongdeok Open Innovation Program. Through this initiative, the company validated its technology and commercial viability alongside a large enterprise. Having demonstrated its potential for market scalability and its technology, the company has solidified the groundwork for strategic partnerships aimed at global market entry.
The two companies plan to introduce next-generation sarcopenia diagnostic and therapeutic solutions through the partnership. This will be achieved by Biobytes’s AI-driven analysis technology, Sarco-Finding for blood and tissue data and applying it to analyze Myomar’s clinical biospecimens from sarcopenia patients.
This would serve as an opportunity for expanding Biobytes’s world-first multicenter sarcopenia biobank cohort database Muscle Bank onto a global scale, enabling establishment of clinical evidence recognized in global market.
Lee Jung-woo, the CEO of Biobytes said, “The collaboration with the Canadian MDx firm serve as a milestone that goes beyond sharing technology to establish global benchmark for sarcopenia. We aim to leverage our combined datasets and advanced analytics to pave the way for successful new drug development for sarcopenia.”
Renowned for both innovation and businesses across diverse sectors, ranging from AI-powered sarcopenia diagnostics aids to muscle enhancing function health diets, it drives the market with its ability to calculate sarcopenia risk in under a minute.
In collaboration with medical institutions such as Wonju severance Christian Hospital, Kangbuk Samsung Hospital, and Seoul St. Mary’s Hospital, Biobytes is building the world’s first multicenter sarcopenia biobank cohort database. Leveraging this database, the company has initiated the technology transfer process for 10 novel sarcopenia biomarkers discovered through its AI-driven platform, Sarco-Finding.
[저작권자ⓒ 메가경제. 무단전재-재배포 금지]
